Richter's 1st-half 2007 profits plummet 41%

5 August 2007

Hungarian drugmaker Richter Gedeon said that the 41% slump in its half year profits, to 18.5 billion forint ($101.3 million), which was in line with forecasts, was a result of an 8.4% drop, to 27.1 billion forint, in domestic sales.

Richter said that the decline, which was despite an 11.5% increase in export revenues to 86.3 billion forint, was a result of domestic price cuts, necessary to keep certain products on the Hungarian reimbursement list. The firm added that it was raising export targets for the rest of the year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight